Therefore, in this nationwide retrospective cohort population-based study, we investigated the risk of major adverse cardiovascular events (MACEs), requiring hospital admission, after breast cancer treatments in patients with hormone receptor–positive early-stage breast cancer, including those admitted in the emergency department. The gene discussed is NR4A1; the disease is breast carcinoma.